
15-16 February 2018 ∣ Manchester, UK
The congress covers novel developments in biomarker discovery and validation, translation into the clinic, personalised healthcare, Big data management, clinical diagnostics development. Key therapeutic focus areas include Immuno Oncology, Neuroscience, Respiratory, Metabolic and Cardiovascular Diseases.
Attended by over 300 biomarker experts, congress will include representatives from the companies including Bayer, Roche, Merck, UCB, Pfizer. The high quality and outstanding interactive programme includes 2 pre-event webinars, 50 expert presentations, a workshop and 8 round table discussions.
Do not miss out on the latest developments in biomarker innovations, state of the art technologies, and drivers into biomarker development such as precision medicine, immuno-assays and screening processes, histology, immunohistochemistry, big data analytics, new technologies in translation and the prediction of patient population.
Free Pre-Congress Live Webinars
Analytical Validation of Assays for the Qualification of BiomarkersThursday 19th October 2017 | 10am GMT
Hosted by John Allinson, Head of Biomarker Strategy at Drug Development Services, LGC & Darren Hodgson, Senior Principal Translational Scientist, Oncology iMED, AstraZeneca
Predictive and Efficacy Biomarkers in Cancer Research
Tuesday 28th November 2018 | 10am GMT
Hosted by Mattias Bergqvist, VP Clinical Development, Biovica International and Sue Burchill, Professor of Adolescent and Paediatric Cancer Research, Leeds Institute of Cancer and Pathology.
Can’t make the dates? Still register and a copy of the webinar recording will be sent to you.
Kelly MacKenzie
Marketing Assistant
Tel: +441865248455